ACLX | tickerfilter.com

Fundamental analysis

33%

Profitability 35%

Dept financing 27%

Liquidity 47%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.06%

1 Month

0.33%

3 Months

67.56%

6 Months

37.93%

1 Year

82.16%

2 Year

121.12%

Key data

Stock price

$114.98

P/E Ratio

0.00

DAY RANGE

$114.98 - $115.07

EPS

-$4.00

52 WEEK RANGE

$47.86 - $115.13

52 WEEK CHANGE

$80.70

MARKET CAP

3.770 B

YIELD

N/A

SHARES OUTSTANDING

58.480 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

2.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$568,944

AVERAGE 30 VOLUME

$937,032

Company detail

CEO: Rami Elghandour
Region: US
Website: arcellx.com
Employees: 80
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

ACLX - Arcellx, Inc.